Study: Two-thirds of new cancer drugs don't extend life

Those drugs are instead approved because of so-called surrogate measures of effectiveness, such as scans showing tumor shrinkage, according to a paper published in JAMA Internal Medicine. Please continue reading from: JSOnline.com NewsWatch